Use of hip resurfacing arthroplasty for the treatment of hip arthritis in younger patients demonstrated a lower rate of revision and complications at short-term follow up, according to study results.
In an ongoing, prospective, multicenter cohort study, researchers have aimed to assess the safety and efficacy of a hip resurfacing implant in 265 patients. The researchers used Harris Hip Score, Euroqol-EQ-5D (EQ-5D) and range of motion to assess patients at the preoperative visit and at 6 weeks, 3 months, 1 year and annually thereafter. Additionally, biplanar radiographs were taken preoperatively, at 1 month and 1 year postoperatively, and annually thereafter.
Study results showed an improvement in Harris Hip Scores from a preoperative average of 56.8 to 96.9 at 2 years and 97 at 4 years, as well as a significant increase in EQ-5D score from 70.6 preoperatively to 88.5 at 1 year and 87.6 at 2 years, according to the researchers.
With regard to implant survivorship at 5 years postoperatively, women had a Kaplan-Meier survival of 94.7% and men had a 98.6% survivorship. Only seven revisions have been recorded to date, according to the researchers.
At 1 year, 267 hips had metal ion testing, at which time the researchers found a median whole blood cobalt level of 1.51 ppb and a median whole blood chromium level of 1.7 ppb. These results increased at 4 years with 112 hips at a 1.56 ppb median whole blood cobalt level and a 1.8 ppb median whole blood chromium level.
Disclosure: See the study for a full list of all authors’ relevant financial disclosures.